CytoSorbents Corporation (CTSO)

[Murph1953]

Thanks much Bertha for that link to BioMedCentral/Critical Care

5th section from the bottom:

Extracorporeal multiorgan support

"While several extracorporeal approaches have been used as adjunctive therapies for organ failures beyond AKI [49, 54, 55, 56, 57, 58, 59, 60], additional clinical outcome data are clearly needed.

"We believe prospective trials performed over the next decade will demonstrate outcome benefits for such approaches as adjunctive therapies (Fig. 2).

"We feel that extracorporeal systems designed to eliminate CO2 (as an adjunct to low tidal volume ventilation) [54] and modulate inflammatory mediators (as an adjunct to sepsis therapy) have the greatest likelihood of showing these benefits.

"With regard to sepsis adjunctive therapies, we predict that mediator modulation will be achieved through both filter-based [57, 58] and hemoperfusion [59, 60] techniques.